Expert Interview
Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Ticker(s): JNJInstitution: Private Practice
- CLinical Interest included skin cancer and psoriasis
- Manages 100 patients with alopecia
- Familiar with CTP-543
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
